Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REVAXIS · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| REVAXIS® | BIOLOGICAL | - |
| DT-Polio® | BIOLOGICAL | - |
Inclusion Criteria: 1. Healthy child without chronic severe disease of either gender, 2. 6 year-old child on vaccination day, 3. Child previously vaccinated with three doses of a diphtheria, tetanus and poliomyelitis containing vaccine given alone or in combination within the first 6 months of life...
REVAXIS is a vaccine developed by Sanofi for protection against diphtheria, and it is also studied for tetanus and poliomyelitis. It is given as a booster dose, including in children, to maintain immunity against these infectious diseases. The vaccine is in Phase 3 clinical development.
REVAXIS is made by Sanofi, which trades under the ticker SNY. Sanofi is the developer responsible for the vaccine's clinical program and manufacturing.
REVAXIS is in Phase 3 clinical development. One Phase 3 trial has been completed, and no active trials are currently listed. The completed trial enrolled 760 participants.
REVAXIS has been evaluated in a completed Phase 3 trial, NCT00447525, titled REVAXIS versus DT Polio as a Second Booster in 6 Year-old Children. The trial enrolled 760 participants in France and studied diphtheria, tetanus, and poliomyelitis.
Yes, REVAXIS and REVAXIS® refer to the same vaccine. The registered trademark symbol is simply a notation used in some documents; both names identify the Sanofi product for diphtheria, tetanus, and poliomyelitis.